FrancophonIA/ELRC3.0 huggingface dataset:
English: The Committee further considered that the benefit/risk balance concerning the use of moxifloxacin up to 14 days in the PID indication remains positive, and that information and recommendations on the use of moxifloxacin, and the measures that should be taken before it is prescribed, are adequately addressed in the ‘contraindications' and ‘special warnings and precautions for use' sections of the EU SPC.
Estonian: moksifloksatsiini kasutamise kohta ning enne manustamist võetavad meetmed, mis on esitatud Euroopa Liidus kehtiva ravimi omaduste kokkuvõtte lõikudes „Vastunäidustused“ ning „Hoiatused ja ettevaatusabinõud kasutamisel“, on asjakohased.
English: Immediate Packaging
Estonian: Ravimvorm Manustamistee Immediate Packaging
English: MA (EU) Number
Estonian: Müügiloa number (Väljamõeldud) nimetus
English: (Invented) name Strength Pharmaceutical Form
Estonian: Õhukese blister polümeerikattega tablett
English: Route of Administration
Estonian: Tugevus
English: Annex I List of the names, pharmaceutical form, strength of the medicinal products, route of administration, marketing authorisation holders in the member states
Estonian: Lisa I Ravimite nimetuste, ravimivormide, tugevuste, manustamisviiside, taotlejate, müügiloa hoidjate loetelu liikmesriikides
English: Giovanni Ogna E Figli S.p.A. Viale Zara 23
Estonian: Giovanni Ogna E Figli S.p.A.
English: Lithuania
Estonian: Itaalia
English: Telmisartan Teva telmisartan
Estonian: Telmisartan Teva telmisartaan
English: It is used in patients who have had problems due to blood clots in the past (such as heart disease, a stroke or artery disease) or who have type 2 diabetes that has damaged an organ (such as the eyes, heart or kidneys).
Estonian: Seda kasutatakse patsientidel, kellel on juba esinenud vere hüübimisest tingitud probleeme (näiteks südamehaigusi, insulte või arteriaalseid haigusi) või kellel on II tüüpi diabeet, mis on mõnda organit (näiteks silmi, südant või neerusid) kahjustanud.
English: The full EPAR for Telmisartan Teva can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Telmisartan Teva kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The European Commission granted a marketing authorisation valid throughout the EU for Telmisartan Teva on 26 January 2010.
Estonian: Euroopa Komisjon andis Telmisartan Teva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 26. jaanuaril 2010.
English: The doctor should monitor the patient's blood pressure closely when starting Telmisartan Teva, and may decide to adjust the patient's blood pressure-lowering medication.
Estonian: Arst peab Telmisartan Tevaga ravi alustamisel patsiendi vererõhku hoolikalt jälgima ning ta võib kohandada patsiendi vererõhku alandava ravimi annust.
English: It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.
Estonian: Lisaks hõlbustab ravim südame tööd vere pumpamisel, mis vähendab tulevaste kardiovaskulaarsete probleemide riski.
English: For more information about treatment with Telmisartan Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Telmisartan Tevaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Other information about Telmisartan Teva
Estonian: Muu teave Telmisartan Teva kohta
English: Telmisartan Teva is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes.
Estonian: Telmisartan Tevat kasutatakse ka kardiovaskulaarsete probleemide (südame- ja veresoonkonnaprobleemide), näiteks südameinfarkti ja insuldi ennetamiseks.
English: For the treatment of essential hypertension, the recommended dose of Telmisartan Teva is 40 mg once a day, but some patients may benefit from using a 20 mg dose.
Estonian: Essentsiaalse hüpertensiooni ravis on Telmisartan Teva soovitatav annus 40 mg üks kord ööpäevas, kuid mõnele patsiendile võib piisata ka 20 mg annusest.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Telmisartan Teva.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For the prevention of cardiovascular problems, the recommended dose is 80 mg once a day.
Estonian: Kardiovaskulaarsete probleemide ennetamisel on soovitatav annus 80 mg üks kord ööpäevas.
English: The Committee recommended that Telmisartan Teva be given marketing authorisation.
Estonian: Komitee soovitas anda Telmisartan Teva müügiloa.
English: Because Telmisartan Teva is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Telmisartan Teva on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samadeks mis võrdlusravimil.
English: Telmisartan Teva is a medicine that contains the active substance telmisartan.
Estonian: Telmisartan Teva on ravim, mis sisaldab toimeainena telmisartaani.
English: reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
Estonian: Kui see ei alanda vererõhku, võib annust suurendada 80 mg-ni või täiendada ravi mõne teise kõrgvererõhuravimiga, näiteks hüdroklorotiasiidiga.
English: Telmisartan Teva is a ‘generic medicine'.
Estonian: Telmisartan Teva on geneeriline ravim.
English: This is a summary of the European public assessment report (EPAR) for Telmisartan Teva.
Estonian: See on ravimi Telmisartan Teva Euroopa avaliku hindamisaruande kokkuvõte.
English: The active substance in Telmisartan Teva, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Telmisartan Teva toimeaine telmisartaan on angiotensiin II retseptori antagonist, mis blokeerib organismis hormooni angiotensiin II toime.
English: Patients with mild or moderately reduced liver function should not receive doses higher than 40 mg a day.
Estonian: Kerge või mõõduka neerupuudulikkusega patsiendid ei tohi võtta suuremat annust kui 40 mg üks kord ööpäevas.
English: The CHMP concluded that, in accordance with EU requirements, Telmisartan Teva has been shown to have comparable quality and to be bioequivalent to Micardis.
Estonian: Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud ravimi Telmisartan Teva võrreldav kvaliteet ja bioekvivalentsus ravimiga Micardis.
English: This means that Telmisartan Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Micardis.
Estonian: See tähendab, et Telmisartan Teva on sarnane võrdlusravimiga Micardis, millel juba on Euroopa Liidus müügiluba.
English: This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a stroke.
Estonian: See vähendab vererõhku ja kõrgvererõhu riske, näiteks insuldi esinemist.
English: Therefore, the CHMP's view was that, as for Micardis, the benefit outweighs the identified risk.
Estonian: Seetõttu on inimravimite komitee arvamusel, et nagu ka Micardise korral, ületab ravimi Telmisartan Teva kasulikkus sellega kaasnevad riskid.
English: Why has Telmisartan Teva been approved?
Estonian: Miks Telmisartan Teva heaks kiideti?
English: What is Telmisartan Teva?
Estonian: Mis on Telmisartan Teva?
English: Telmisartan Teva is used in adults who have essential hypertension (high blood pressure).
Estonian: Telmisartan Tevat kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) ravimiseks täiskasvanutel.
English: Because Telmisartan Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Micardis.
Estonian: Et Telmisartan Teva on geneeriline ravim, piirdusid uuringud katsetega, milles näidati Telmisartan Teva bioekvivalentsust võrdlusravimiga Micardis.
English: Patients with severely reduced kidney function should receive a lower starting dose of 20 mg once a day.
Estonian: Raske neerupuudulikkusega patsiendid peavad ravi alustama väiksema annusega, 20 mg üks kord ööpäevas.
English: What are the benefits and risks of Telmisartan Teva?
Estonian: Milles seisneb Telmisartan Teva kasulikkus ja mis riskid ravimiga kaasnevad?
English: How has Telmisartan Teva been studied?
Estonian: Kuidas Telmisartan Tevat uuriti?
English: What is Telmisartan Teva used for?
Estonian: Milleks Telmisartan Tevat kasutatakse?
English: How is Telmisartan Teva used?
Estonian: Kuidas Telmisartan Tevat kasutatakse?
English: How does Telmisartan Teva work?
Estonian: Kuidas Telmisartan Teva toimib?
English: After a 28-day course of treatment, the patient stops treatment for 28 days, before starting another 28-day course.
Estonian: 28-päevase ravikuuri järel peab patsient 28 päeva vahet, enne kui alustab järgmist 28-päevast ravikuuri.
English: Further information on Vantobra can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/vantobra
Estonian: Lisateave Vantobra kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/vantobra
English: What measures are being taken to ensure the safe and effective use of Vantobra?
Estonian: Mis meetmed võetakse, et tagada Vantobra ohutu ja efektiivne kasutamine?
English: Treatment courses may be repeated for as long as the doctor considers the patient to be benefiting from treatment.
Estonian: Ravikuure tohib korrata nii kaua, kuni arst arvab, et need on patsiendile kasulikud.
English: Vantobra1 (tobramycin)
Estonian: Vantobra1 (tobramütsiin)
English: The European Medicines Agency decided that Vantobra's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Vantobra kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: The recommended dose is one ampoule twice a day, ideally 12 hours apart.
Estonian: Soovitatav annus on üks ampull kaks korda ööpäevas, soovitatavalt 12-tunnise vahega.
English: Other information about Vantobra
Estonian: Muu teave Vantobra kohta
English: Vantobra is therefore easier to use and might help patients to stick to their treatment.
Estonian: Seega on Vantobra kasutamine lihtsam, mis võib aidata patsientidel järgida ravi.
English: The Agency noted that safety profile of inhaled tobramycin was well known.
Estonian: Seoses ohutusega märkis amet, et inhaleeritava tobramütsiini ohutusprofiil on hästi teada.
English: There were no unexpected safety issues with Vantobra.
Estonian: Vantobra korral puuduvad ootamatud ohutusprobleemid.
English: What is Vantobra and what is it used for?
Estonian: Mis on Vantobra ja milleks seda kasutatakse?
English: This means that it is similar to a ‘reference medicine' containing the same active substance, tobramycin; however, Vantobra has a higher amount of the active substance.
Estonian: See tähendab, et see on sarnane sama toimeainet sisaldava võrdlusravimiga, kuid Vantobra sisaldab toimeainet rohkem.
English: Side effects reported with Vantobra are carefully evaluated and any necessary action taken to protect patients.
Estonian: Vantobra kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: If the patient is also receiving other inhaled treatments or chest physiotherapy, it is recommended that Vantobra is used last.
Estonian: Kui patsient saab ka muid inhaleeritavaid ravimeid või rindkere füsioteraapiat, on soovitatav kasutada ravimit Vantobra viimasena.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vantobra have been included in the summary of product characteristics and the package leaflet.
Estonian: Ravimi Vantobra ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: As for all medicines, data on the use of Vantobra are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse ravimi Vantobra kasutamise kohta pidevat järelevalvet.
English: For more information about using Vantobra, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet ravimi Vantobra kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: However, the following side effects are seen in up to 1 in 100 patients: dyspnoea (difficulty breathing), dysphonia (hoarseness), pharyngitis (sore throat) and cough.
Estonian: 1-10 patsiendil 1000st võivad siiski esineda järgmised kõrvalnähud: düspnoe (raskendatud hingamine), düsfoonia (kähedus), farüngiit (kurguvalu) ja köha.
English: 1 Previously known as Tobramycin PARI.
Estonian: 1 Varasem nimetus Tobramycin PARI
English: Cystic fibrosis is an inherited disease in which thick mucus builds up in the lungs that allows bacteria to grow more easily, causing infections.
Estonian: Tsüstiline fibroos on pärilik haigus, mille korral koguneb kopsu paks lima, mis soodustab bakterite kasvu, põhjustades infektsioone.
English: P. aeruginosa is a frequent cause of infections in cystic fibrosis patients.
Estonian: P. aeruginosa põhjustab tsüstilise fibroosiga patsientidel sageli infektsioone.
English: Vantobra is a ‘hybrid medicine'.
Estonian: Vantobra on hübriidravim.
English: The results of the study showed that Vantobra can be considered comparable to Tobi.
Estonian: Uuringutulemused tõendasid, et ravimit Vantobra saab pidada Tobiga võrreldavaks ravimiks.
English: The Agency noted that inhaled tobramycin was the ‘gold standard' for treating P. aeruginosa infection in patients with cystic fibrosis and that some patients cannot use the dry powder form because of unacceptable side effects.
Estonian: Amet märkis, et inhaleeritav tobramütsiin on tsüstilise fibroosiga patsientide P. aeruginosa infektsiooni ravis standardravi ja et mõni patsient ei saa kasutada kuiva pulbri ravimvormi, sest nad ei talu seda.
English: Tobramycin has been used for several years to treat P. aeruginosa infection in patients with cystic fibrosis and the applicant submitted data from the literature to support the use of Vantobra.
Estonian: Tobramütsiini on mitu aastat kasutatud P. aeruginosa infektsiooni raviks tsüstilise fibroosiga patsientidel ja müügiloa taotleja esitas Vantobra kasutamise toetuseks kirjandusandmed.
English: How does Vantobra work?
Estonian: Kuidas Vantobra toimib?
English: It works by interfering the production of proteins that P. aeruginosa needs to build its cell walls, resulting in damage to the bacteria, which eventually kills them.
Estonian: Ravim takistab P. aeruginosa rakuseinte moodustumiseks vajalike valkude tootmist, kahjustades sellega baktereid, mis lõpuks hävivad.
English: The active substance in Vantobra, tobramycin, belongs to the group of antibiotics known as ‘aminoglycosides'.
Estonian: Vantobra toimeaine tobramütsiin kuulub aminoglükosiid-antibiootikumide rühma.
English: In addition, it takes less time to inhale Vantobra than other tobramycin nebulisers and the time it takes is comparable to the time it takes to inhale the dry powder.
Estonian: Lisaks on Vantobra inhaleerimine kiirem kui muude tobramütsiini nebulisaatoritega ja võrreldav kuiva pulbri inhaleerimise kestusega.
English: The reference medicine for Vantobra is Tobi.
Estonian: Vantobra võrdlusravim on Tobi.
English: What are the risks associated with Vantobra?
Estonian: Mis riskid ravimiga Vantobra kaasnevad?
English: Vantobra is an antibiotic used for treating long-term lung infection caused by the bacteria Pseudomonas aeruginosa in patients aged six years and older who have cystic fibrosis.
Estonian: Vantobra on antibiootikum, mida kasutatakse bakteri Pseudomonas aeruginosa põhjustatud kroonilise kopsuinfektsiooni raviks vähemalt 6-aastastel tsüstilise fibroosiga patsientidel.
English: An overview of Vantobra and why it is authorised in the EU
Estonian: Ülevaade ravimist Vantobra ja ja ELis müügiloa väljastamise põhjendus
English: What benefits of Vantobra have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Vantobra kasulikkus?
English: Vantobra is inhaled using a device called Tolero nebuliser, which converts the solution in the ampoule into a fine mist.
Estonian: Ravimit Vantobra inhaleeritakse Tolero nebulisaatoriga, mis muudab ampullis oleva lahuse peeneks uduks.
English: For these patients Vantobra, which is inhaled as a solution from a nebuliser, would be a useful alternative.
Estonian: Nende patsientide jaoks on kasulik alternatiiv Vantobra, mis on nebulisaatoriga inhaleeritav lahus.
English: How is Vantobra used?
Estonian: Kuidas ravimit Vantobra kasutatakse?
English: Vantobra is available as a nebuliser solution in single-dose ‘ampoules'.
Estonian: Ravimit Vantobra turustatakse nebuliseeritava lahusena üheannuselistes ampullides.
English: Side effects with Vantobra are not common.
Estonian: Vantobra kasutamisel ei esine kõrvalnähte sageli.
English: In addition, a ‘bioequivalence' study in 58 patients with cystic fibrosis aged 6 years and above determined whether Vantobra produces similar levels of the active substance in the body as the reference medicine, Tobi.
Estonian: Lisaks korraldas müügiloa taotleja bioekvivalentsuse uuringu, milles osales 58 vähemalt 6-aastast tsüstilise fibroosiga patsienti.
English: Beacon Pharmaceuticals Limited,
Estonian: Ühendkuningriik Beacon Pharmaceuticals Limited,
English: Praceta do Farol, lote 101 Cascais 2750-341
Estonian: Praceta do Farol, lote 101 Cascais 2750-341 Portugal
English: Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration and marketing authorisation holders in the member states
Estonian: Nimetuste, ravimvormide, ravimite tugevuste, manustamisteede ja müügiloa hoidjate loetelu liikmesriikides
English: Cólquide, 6 - Portal 2, 1º-Oficina F
Estonian: LABORATORIO, S.A. Cólquide, 6 - Portal 2, 1º-Oficina F
English: Kent DA2 6SL
Estonian: Kent DA2 6SL United Kingdom
English: Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A. 2, A. Fleminga Str.
Estonian: Tarchomińskie Zakłady Farmaceutyczne "Polfa" S.A.
English: Luxembourg Profile Pharma Limited Chichester Business Park City Fields Way
Estonian: Ühendkuningriik Profile Pharma Limited Chichester Business Park City Fields Way
English: 03-176 Warsaw Poland
Estonian: 2, A. Fleminga Str. 03-176 Warsaw Poland
English: Tunbridge Wells, Kent TN1 1YG
Estonian: Tunbridge Wells, Kent
English: Colistimethat-Natrium Infectopharm I.E. Pulver zur Herstellung einer Injektionsoder Infusionslösung powder for solution for injection/infusion
Estonian: Colistimethat-Natrium Infectopharm I.E. Pulver zur Herstellung einer Injektionsoder Infusionslösung
English: Promixin nasal use
Estonian: Promixin nasaalne
English: Colixin 1 milijun IU prašak za otopinu za injekciju powder for solution for injection
Estonian: Colixin 1 milijun IU prašak za otopinu za injekciju
English: COLIMYCINE 1.000.000 U.I., poudre et solvant pour solution injectable powder and solvent for solution for injection
Estonian: COLIMYCINE 1.000.000 U.I., poudre et solvant pour solution injectable
English: 55134, Kalamaria, Thessaloniki Greece
Estonian: ALLERTEC HELLAS AE 74 Karamanli str. 55134, Kalamaria, Thessaloniki Greece
English: GES GENÉRICOS ESPAÑOLES LABORATORIO, S.A.
Estonian: GES GENÉRICOS ESPAÑOLES
English: Tadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung powder for solution for infusion
Estonian: Tadim 1 Million I.E. Pulver zur Herstellung einer Infusionslösung
English: COLIMYCINE 1 MUI, poudre et solvant pour inhalation par nébuliseur powder and solvent for nebuliser solution
Estonian: COLIMYCINE 1 MUI, poudre et solvant pour inhalation par nébuliseur
English: Forest Pharma B.V. Newtonlaan 115
Estonian: Forest Pharma B.V.
English: Colistimethate sodium 1 million international units powder for solution for injection or infusion powder for solution for injection/infusion
Estonian: Colistimethate sodium 1 million international units powder for solution for injection or infusion
English: Colistimetato de sodio GES 1 MUI polvo para solución inyectable/para inhalación por nebulizador powder for solution for injection, powder for nebuliser solution
Estonian: Colistimetato de sodio GES 1 MUI polvo para solución inyectable/para inhalación por nebulizador
English: Pulver zur Herstellung einer Lösung für einer Infusionslösung powder for solution for infusion
Estonian: Pulver zur Herstellung einer Lösung für einer Infusionslösung
English: Colixin 1 MUI polvo para solución inyectable o para solución para inhalación por nebulizador powder for solution for injection, powder for nebuliser solution
Estonian: Colixin 1 MUI polvo para solución inyectable o para solución para inhalación por nebulizador
English: powder for solution for infusion
Estonian: powder for solution for injection
English: Colomycin Injection 2 million international units powder for soln for inj, infusion or inhalation powder for solution for injection
Estonian: Colomycin Injection 2 million international units powder for soln for inj, infusion or inhalation
English: Pulver zur Herstellung einer Injektions-/Infusionslösung powder for solution for injection/infusion
Estonian: Pulver zur Herstellung einer Injektions-/Infusionslösung
English: powder for solution for injection/infusion/ inhalation
Estonian: Powder for solution for injection, infusion or inhalation
English: Colomycin Injection 1million International Units powder for solution for injection, infusion or inhalation powder for solution for injection/infusion/ inhalation
Estonian: Colomycin Injection 1million International Units powder for solution for injection, infusion or inhalation
English: Colistimethatnatrium "Xellia" 1000000 I.U.
Estonian: Colistimethatnatrium "Xellia" 1000000 RÜ süste-/infusioonilahuse pulber intravenoosne
English: Belgium Forest Laboratories UK Ltd. Riverbridge House
Estonian: Ühendkuningriik Forest Laboratories UK Limited Riverbridge House Anchor Boulevard
English: Crossways Business Park Dartford
Estonian: Crossways Business Park Dartford, Kent DA2 6SL United Kingdom
English: Colomycin Injection 1 million international units powder for soln for inj, infusion or inhalation powder for solution for injection, infusion or inhalation intramuscular use, intravenous use, inhalation use
Estonian: Colomycin Injection 1 million international units powder for soln for inj, infusion or inhalation
English: powder for solution for injection, injection or inhalation intramuscular use, intravenous use, inhalation use
Estonian: 1000000 RÜ süstelahuse pulber, infusioon või inhalatsioon intramuskulaarne, intravenoosne, inhalatsioon
English: Promixin 1 million international units (IU) powder for solution for infusion powder for solution for injection intramuscular use, intravenous use
Estonian: Promixin 1 million international units (IU) powder for solution for infusion
English: Colistin ForestTrockenstechampullen mit Lösungsmittel powder and solvent for suspension for injection, nebuliser solution intramuscular use, intravenous use, inhalation use
Estonian: 1000000 RÜ süstesuspensiooni pulber ja lahusti, nebuliseeritav lahus intramuskulaarne, intravenoosne, inhalatsioon
English: The antibodies will help to protect against the disease.
Estonian: Antikehad aitavad kaitsta haiguse eest.
English: Long-term antibody levels were similar with both schedules.
Estonian: Pikaajaline antikehade sisaldus oli sarnane mõlema skeemi korral.
English: Vaccination must be postponed in people with recent severe fever.
Estonian: Vaktsineerimine tuleb edasi lükata patsientidel, kellel on hiljuti olnud kõrge palavik.
English: Ixiaro received a marketing authorisation valid throughout the EU on 31 March 2009.
Estonian: Ixiaro on saanud müügiloa, mis kehtib kogu ELis, 31. märtsil 2009.